Forum Hiv
Vuoi reagire a questo messaggio? Crea un account in pochi click o accedi per continuare.

GENEVAX della Profectus BioSciences

Andare in basso

GENEVAX della Profectus BioSciences Empty GENEVAX della Profectus BioSciences

Messaggio Da Gex Gio 6 Gen - 11:32

Parte la sperimentazione di un nuovo vaccino il GENEVAX IL-12 pDNA della Profectus BioSciences.
Il vaccino contiene multi-antigen HIV plasmid DNA (pDNA).

[Devi essere iscritto e connesso per vedere questo link]

Profectus BioSciences commences GENEVAX IL-12 phase 1 study for HIV
6. January 2011 05:56



Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, and the AIDS Clinical Trials Group (ACTG) announced today the initiation of a phase 1 study of Profectus' multi-antigen HIV plasmid DNA (pDNA) vaccine administered with various doses of GENEVAX™ interleukin-12 (IL-12) pDNA adjuvant and delivered using the electroporation (EP) based TriGrid™delivery system (TriGrid) developed by Ichor Medical Systems. The multi-center study is being sponsored by the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study is being conducted by the NIAID-funded ACTG under a protocol designated A5281.

The phase 1, placebo-controlled, dose-escalation study will enroll 60 HIV-infected subjects on stable anti-retroviral therapy. It will assess the safety and immunogenicity of a fixed dose of the Profectus therapeutic multi-antigen HIV pDNA vaccine administered with escalating doses of GENEVAX™ IL-12 pDNA adjuvant and delivered with the TriGrid device. Non-human primate studies conducted by Profectus have demonstrated that the combination of IL-12 pDNA adjuvant plus EP delivery significantly increases the immunogenicity of pDNA vaccines compared to delivery with either EP alone or IL-12 alone. In a separate clinical study (HVTN 080), a fixed dose level of GENEVAX™ IL-12 is currently being evaluated for its ability to augment immune responses to an experimental HIV pDNA vaccine delivered with EP in HIV-negative volunteers. As previously reported, the interim data from that study indicate GENEVAX™IL-12 significantly increased the percentage of vaccine recipients that mounted antigen-specific T-cell responses as compared to HIV pDNA alone. In addition to improving response rates, the inclusion of GENEVAX™ IL-12 was also observed to significantly lessen injection site discomfort.

Dr. John Eldridge, Profectus BioSciences' Chief Scientific Officer, said: "Profectus is very pleased to collaborate with the NIH and the ACTG in the development of a therapeutic vaccine with the potential to improve viral control and clinical outcome in subjects battling HIV infection. The recent clinical results that validate the adjuvant activity of GENEVAX™ IL-12 in normal healthy volunteers provide a level of confidence that a significant improvement in immunogenicity will be obtained relative to the therapeutic HIV vaccines tested to date."

Source: Profectus BioSciences

Gex
Gex
Admin

Messaggi : 2565
Data d'iscrizione : 20.12.10

Torna in alto Andare in basso

GENEVAX della Profectus BioSciences Empty Re: GENEVAX della Profectus BioSciences

Messaggio Da Gex Lun 10 Gen - 8:51

[Devi essere iscritto e connesso per vedere questo link]

Profectus BioSciences Announces Initiation Of Clinical Trial Of IL-12 Enhanced Therapeutic HIV DNA Vaccine Delivered Using Electroporation

Main Category: HIV / AIDS
Also Included In: Clinical Trials / Drug Trials
Article Date: 10 Jan 2011 - 0:00 PST


email to a friend printer friendly opinions

Ads by Google
Clinical Trials - Daily Clinical Trials Updates Detailed Drug Pipelines - [Devi essere iscritto e connesso per vedere questo link]

Clinical Trials Australia - Novotech - The Australian CRO Full Clinical Service - Australasia - [Devi essere iscritto e connesso per vedere questo link]

Arrowhead's ePRO Solution - See it. Know it. Smartphone. Web. Tablet Computer. - [Devi essere iscritto e connesso per vedere questo link]
Current Article Ratings:
Patient / Public:

Healthcare Prof:


Find other articles on: "hiv"

Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, and the AIDS Clinical Trials Group (ACTG) has announced the initiation of a phase 1 study of Profectus' multi-antigen HIV plasmid DNA (pDNA) vaccine administered with various doses of GENEVAX™ interleukin-12 (IL-12) pDNA adjuvant and delivered using the electroporation (EP) based TriGrid™delivery system (TriGrid) developed by Ichor Medical Systems. The multi-center study is being sponsored by the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study is being conducted by the NIAID-funded ACTG under a protocol designated A5281.

The phase 1, placebo-controlled, dose-escalation study will enroll 60 HIV-infected subjects on stable anti-retroviral therapy. It will assess the safety and immunogenicity of a fixed dose of the Profectus therapeutic multi-antigen HIV pDNA vaccine administered with escalating doses of GENEVAX™ IL-12 pDNA adjuvant and delivered with the TriGrid device. Non-human primate studies conducted by Profectus have demonstrated that the combination of IL-12 pDNA adjuvant plus EP delivery significantly increases the immunogenicity of pDNA vaccines compared to delivery with either EP alone or IL-12 alone. In a separate clinical study (HVTN 080), a fixed dose level of GENEVAX™ IL-12 is currently being evaluated for its ability to augment immune responses to an experimental HIV pDNA vaccine delivered with EP in HIV-negative volunteers. As previously reported, the interim data from that study indicate GENEVAX™IL-12 significantly increased the percentage of vaccine recipients that mounted antigen-specific T-cell responses as compared to HIV pDNA alone. In addition to improving response rates, the inclusion of GENEVAX™ IL-12 was also observed to significantly lessen injection site discomfort.

Dr. John Eldridge, Profectus BioSciences' Chief Scientific Officer, said: "Profectus is very pleased to collaborate with the NIH and the ACTG in the development of a therapeutic vaccine with the potential to improve viral control and clinical outcome in subjects battling HIV infection. The recent clinical results that validate the adjuvant activity of GENEVAX™ IL-12 in normal healthy volunteers provide a level of confidence that a significant improvement in immunogenicity will be obtained relative to the therapeutic HIV vaccines tested to date."

About Profectus' Multi-Antigen Therapeutic HIV pDNA Vaccine and GENEVAX™ IL-12 pDNA

Profectus' multi-antigen therapeutic pDNA vaccine consists of two plasmid vectors designed to induce immune responses against the env, gag, pol, nef, tat, and vif proteins of HIV. GENEVAX™ IL-12 is a proprietary pDNA vector that expresses the immune modulating cytokine human interleukin-12. The pDNA vectors are supplied for clinical use in a proprietary formulation containing the anesthetic bupivacaine. In addition to its anesthetic properties, bupivacaine has been shown to enhance the efficiency of DNA vaccines and to provide a liquid formulation with multi-year stability.

Source:
Profectus BioSciences, Inc.
Gex
Gex
Admin

Messaggi : 2565
Data d'iscrizione : 20.12.10

Torna in alto Andare in basso

Torna in alto


 
Permessi in questa sezione del forum:
Non puoi rispondere agli argomenti in questo forum.